A Phase 3 interventional study of VX-659/TEZ/IVA and TEZ/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 46 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-10-17.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated — 3 open to participants now, 8 under way, 5 of them phase 3. Cystic Fibrosis · Vertex Pharmaceuticals Incorporated.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 44th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 62 in phase 3, and was the 72nd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →3 of the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated are open now, in 10 countries. Recruiting first, the newest first:
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States, Australia, Canada and 7 more countries
Ages 1+
By country, each count listing its studies:
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 24 · Phase 3 62 · Phase 4 2
First in 2007; this study’s year is marked. 13 started in 2018.
This study's enrollment of 116 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 73 across the 116 interventional studies, 79 across the 5 observational. Of the 112 that completed or were terminated, 80 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
4 of the studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation (F/F).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
Drug: TEZ/IVA · Drug: IVA · Drug: Placebo
Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
Drug: VX-659/TEZ/IVA · Drug: IVA · Drug: Placebo
Participants received VX-659/TEZ/IVA orally once daily in the morning.
Also known as: VX-659/VX-661/VX-770, VX-659/tezacaftor/ivacaftor
Drug pages: Tezacaftor · Ivacaftor
Participants received TEZ/IVA orally once daily in the morning.
Also known as: VX-661/VX-770, tezacaftor/ivacaftor
Participants received IVA orally once daily in the evening.
Also known as: VX-770, ivacaftor
Participants received placebo matched TEZ/IVA orally once daily in the morning.
Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline at Week 4
Absolute Change in Sweat Chloride (SwCl)
Sweat samples were collected using an approved collection device.
Time frame: From Baseline at Week 4
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline at Week 4
Safety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to Week 8)
Observed Pre-Dose Concentration (Ctrough) of VX-659, TEZ, TEZ Metabolite (M1-TEZ), and IVA
Time frame: From Day 1 and Week 4
A total of 116 participants were enrolled in the study, of which 5 participants were included in the run-in period but were not dosed in TC treatment period. Results are presented for 111 participants dosed in the TC treatment period.
| Milestone | TEZ/IVA | VX-659/TEZ/IVA TC |
|---|---|---|
| Started | 57 | 54 |
| Completed | 57 | 54 |
| Not completed | 0 | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | TEZ/IVA | VX-659/TEZ/IVA TC |
|---|---|---|
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 0.3 ± 0.9 | 10.2 ± 0.9 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | TEZ/IVA | VX-659/TEZ/IVA TC |
|---|---|---|
| Absolute Change in Sweat Chloride (SwCl) | 1.5 ± 1.8 | -47.2 ± 1.9 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | TEZ/IVA | VX-659/TEZ/IVA TC |
|---|---|---|
| Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score | 3.0 ± 1.7 | 16.5 ± 1.7 |
| participants | TEZ/IVA | VX-659/TEZ/IVA TC |
|---|---|---|
| Participants with AEs | 31 | 33 |
| Participants with SAEs | 0 | 2 |
| nanogram per milliliter (ng/mL) | TEZ/IVA | VX-659/TEZ/IVA TC |
|---|---|---|
| Week 4: VX-659 | — | 720 ± 589 |
| Day 1: TEZ | 1780 ± 832 | 1590 ± 1020 |
| Week 4: TEZ | 1730 ± 885 | 1280 ± 594 |
| Day 1: M1-TEZ | 5170 ± 1620 | 4840 ± 1860 |
| Week 4: M1-TEZ | 5010 ± 1810 | 4730 ± 1380 |
| Day 1: IVA | 717 ± 616 | 563 ± 400 |
| Week 4: IVA | 722 ± 642 | 401 ± 211 |
Collected over From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to Week 8). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TEZ/IVA | 0/57 (0%) | 0/57 (0%) | 19/57 (33.3%) |
| VX-659/TEZ/IVA TC | 0/54 (0%) | 2/54 (3.7%) | 23/54 (42.6%) |
| Event | TEZ/IVA | VX-659/TEZ/IVA TC |
|---|---|---|
| DepressionPsychiatric disorders | 0/57 | 1/54 |
| Suicidal ideationPsychiatric disorders | 0/57 | 1/54 |
| ConstipationGastrointestinal disorders | 0/57 | 1/54 |
| Event | TEZ/IVA | VX-659/TEZ/IVA TC |
|---|---|---|
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 0/57 | 9/54 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 9/57 | 2/54 |
| HeadacheNervous system disorders | 5/57 | 3/54 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/57 | 4/54 |
| C-reactive protein increasedInvestigations | 0/57 | 4/54 |
| DiarrhoeaGastrointestinal disorders | 0/57 | 4/54 |
| Alanine aminotransferase increasedInvestigations | 2/57 | 3/54 |
| Aspartate aminotransferase increasedInvestigations | 1/57 | 3/54 |
| Age, Continuous(years) | TEZ/IVA | VX-659/TEZ/IVA TC | Total |
|---|---|---|---|
| Mean | 26.2 ± 9.1 | 28.3 ± 9.6 | 27.2 ± 9.3 |
| Sex: Female, Male(Participants) | TEZ/IVA | VX-659/TEZ/IVA TC | Total |
|---|---|---|---|
| Female | 33 | 26 | 59 |
| Male | 24 | 28 | 52 |
| Ethnicity (NIH/OMB)(Participants) | TEZ/IVA | VX-659/TEZ/IVA TC | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 56 | 52 | 108 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | TEZ/IVA | VX-659/TEZ/IVA TC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 56 | 54 | 110 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Forced Expiratory Volume in 1 Second (ppFEV1)(percentage points) | TEZ/IVA | VX-659/TEZ/IVA TC | Total |
|---|---|---|---|
| Mean | 62.9 ± 14.9 | 62.0 ± 14.8 | 62.4 ± 14.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Sep 2018, 4 months.
Results were first posted in Oct 2019, 1 year after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 4 months is below that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vertex Pharmaceuticals Incorporated →